EA
SAGE

Emerald Advisers’s Sage Therapeutics SAGE Stock Holding History

Emerald Advisers’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-140
Closed -$10K – 298
2019
Q4 		$10K Buy
+140
New +$17.2K ﹤0.01% 329
2019
Q2 		– Sell
-1,280
Closed -$204K – 268
2019
Q1 		$204K Sell
1,280
-2,631
-67% -$381K 0.01% 241
2018
Q4 		$375K Sell
3,911
-574
-13% -$65.7K 0.02% 204
2018
Q3 		$634K Sell
4,485
-117
-3% -$18.1K 0.02% 196
2018
Q2 		$720K Sell
4,602
-148,311
-97% -$23.3M 0.03% 196
2018
Q1 		$24.6M Sell
152,913
-15,872
-9% -$2.69M 0.99% 31
2017
Q4 		$27.8M Buy
168,785
+93,106
+123% +$9.03M 1.07% 28
2017
Q3 		$4.71M Sell
75,679
-107,125
-59% -$8.41M 0.19% 118
2017
Q2 		$14.6M Buy
182,804
+37,786
+26% +$2.73M 0.61% 72
2017
Q1 		$10.3M Buy
+145,018
New +$8.49M 0.42% 91

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Emerald Advisers's SAGE Position: Q1 2020 in Review

Emerald Advisers sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 140 shares — an estimated $10K sold.

Emerald Advisers first reported a position in SAGE in Q1 2017 and held it in 10 quarters. The position peaked at $27.8M in Q4 2017. 230 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

  • Emerald Advisers reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Emerald Advisers sold 140 Sage Therapeutics shares in Q1 2020, an estimated $10K.
  • Emerald Advisers first reported a position in Sage Therapeutics in Q1 2017 and held it in 10 quarters.
  • Emerald Advisers's Sage Therapeutics position peaked at $27.8M in Q4 2017.
  • 230 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on Emerald Advisers's 13F filing for Q1 2020, filed 30 Apr 2020.